Innovative Approaches to Clinical Research Monitoring: The Power of Ingenuity at Memorial Sloan Kettering Cancer Center

S. Sanchez-Molero Perez, A. Granobles, K. Mantha-Thaler, L. Bello-Matricaria, K. Yataghene

Memorial Sloan Kettering Cancer Center

1. Background
The risk-based monitoring (RBM) approach prioritizes oversight of clinical trials based on potential risk to study data quality and patient safety. This approach has shown no evidence of inferiority compared to extensive onsite monitoring in terms of critical or major monitoring findings, according to a recent Cochrane review of monitoring strategies. Furthermore, staff resource was three to fivefold higher with extensive onsite monitoring. At Memorial Sloan Kettering Cancer Center (MSK), the number of active institutional therapeutic and diagnostic studies has increased 179 percent in the last three years, accruing over 4,700 participants in 2022. It is crucial to design strategies that maximize the power of monitoring to increase the reach of monitors to identify and mitigate risks to data quality and patient safety, while improving the efficiency of monitoring.

2. Goals
   1. Maximize the efficiency of an RBM strategy to ensure proper oversight of investigator-initiated Trials (IIT)
   2. Streamline the review of critical study areas such as eligibility and informed consent procedures by optimizing the process to reach as many participants as possible

3. Solutions and Methods
The Clinical Research Quality Assurance (CRQA) Monitoring team developed and implemented a multidisciplinary RBM strategy aimed to identify areas that pose the highest risk to participant safety and data quality while minimizing low yield monitoring activities through process automation. The following priorities have been established:

   1. High-risk trials: RBM of IIT portfolio: A risk assessment tool selects single-center IIT for which a customized RBM plan is developed. Study participants are reviewed based on a targeted source data verification calendar focused on primary and secondary study endpoints.
   2. High-risk processes: Eligibility Checklist Verification Program: A randomized sample of research participants undergo an independent review to ensure that registration and eligibility procedures are followed and are compliant with internal and federal regulations.
   3. Low-yield monitoring activities: Process automation minimizes the possibility of deficiencies and the need for broad monitoring, focusing on compliance areas instead of transcription errors.

4. Outcomes
Our strategy has allowed prioritization of monitoring activities, selecting high-risk trials for customized RBM monitoring, and broad oversight of high-risk processes shared by clinical trials, such as eligibility and informed consent. Additionally, process automation has helped identify areas where monitoring can be reasonably waived without impacting trial safety. Over the past three years, this innovative approach to RBM has allowed the seven members of the CRQA Monitoring team to ensure focused oversight of more than 300 different studies and more than 1,000 study participants per year, providing an additional layer of oversight of participant safety and data quality. Additionally, the findings identified
during these reviews have helped direct education efforts across MSK, further increasing the reach of
the CRQA Monitoring team.

5. Lessons Learned and Future Directions
A multidisciplinary approach to monitoring can reduce the need for extensive visits and increase
efficiency tailoring monitoring activities to the areas of highest risk. While some automation of
processes has already been achieved, a true integration between the electronic medical record (EMR)
and case report forms (CRFs) will furthermore streamline monitoring activities.